Last reviewed · How we verify
CARFENTANIL
At a glance
| Generic name | CARFENTANIL |
|---|---|
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Opioidergic and Noradrenergic Systems in Central Parkisonian Pain (NA)
- Multi-System Analysis of Opioid Receptor Binding (PHASE1)
- Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing (PHASE1)
- Investigating the Mu:Kappa Opioid Receptor Imbalance in Alcohol Use Disorder (EARLY_PHASE1)
- Food Intake, Endocrine Factors and Brown Fat (NA)
- Study of the in Vivo Expression of MU Opioid Receptors Using PET and the Selective Tracer [C-11] Carfentanil in Normal Weight and Obese Subjects
- Neuromolecular Risk Factors for Obesity (PROSPECT) (NA)
- Towards Individualized Deep Brain Stimulation Treatment of Chronic Neuropathic Pain (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CARFENTANIL CI brief — competitive landscape report
- CARFENTANIL updates RSS · CI watch RSS